Do you want to read an article? Please log in or register.
TROPION-Lung01: Favorable QoL outcomes with Dato-DXd in patients with pretreated advanced or metastatic NSCLC
Lung, Respiratory and Thoracic Cancer
ELCC 2025
Related content
ESMO 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Dato-DXd benefits patients with advanced non-squamous NSCLC with or without brain metastases
WCLC 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Quantitative Continuous Scoring of TROP2 Normalized Membrane Ratio Predicts Clinical Outcomes in Patients With NSCLC
WCLC 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Datopotamab deruxtecan shows a clinically meaningful trend toward improved OS versus docetaxel in patients with NSCLC
Lung, Respiratory and Thoracic Cancer
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
J Clin Oncol
Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J, TROPION-Lung01 Trial Investigators
doi: 10.1200/JCO-24-01544
Skin Cancer
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study
Eur J Cancer
Schadendorf D, Lord-Bessen J, Ejzykowicz F, Shi L, Yu P, Srinivasan S
doi: 10.1016/j.ejca.2024.115099
Genitourinary Cancer
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
Lancet Oncol
Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T
doi: 10.1016/S1470-2045(25)00158-5
Lung, Respiratory and Thoracic Cancer
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
Lung Cancer
Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel MH, Linardou H, Chul Cho B, Roberts-Thomson R, Tanaka K, Blais N, Schvartsman G, Holmskov Hansen K, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S
doi: 10.1016/j.lungcan.2024.107921
Lung, Respiratory and Thoracic Cancer
Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland
J Med Econ
Wislez M, Giannopoulou A, Borget I, Lindsay C, Rothschild SI, Vincent B, Milce J, Sultan I, Stollenwerk B, Pless M
doi: 10.1080/13696998.2025.2535225
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Thorac Oncol
Kilickap S, Baramidze A, Sezer A, Özgüroğlu M, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Fuang HG, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, Li Y, Zhu C, Kaul M, Perez J, Seebach F, Lowy I, Pouliot JF, Kim E, Magnan H
doi: 10.1016/j.jtho.2025.03.033